The fight against COVID19
23.82k followers • 14 symbols Watchlist by TREA
Follow this list to discover and track the stock of publicly traded companies with COVID-19 related treatment and healthcare plans.
Curated by TREA
TREA analyses over 100 million data points, interactions, relationships on company research and development activities, allowing investors to quickly gain insight without having to go through complex regulatory filings. Primary data sources include: US FDA (US Food and Drug Administration), US NIH (US National Institutes of Health), USPTO (US Patent and Trademark Office). The search parameters for generating this watchlist were (1) Above sector average Innovation Index score, (2) IP history of at least 5 years (3) COVID19 (4) 2019-nCov (5) SARS-CoV-2, among others.
Performance
| Watchlist | Change today | 1-month return | 1-year return | Total return |
|---|---|---|---|---|
| The fight against COVID19 | -1.11% | - | - | - |
| ^GSPC | +0.12% | +6.77% | +26.51% | +5602.44% |
14 symbols
| Symbol | Company name | Last price | Change | % change | Market time | Volume | Avg vol (3-month) | Market cap |
|---|---|---|---|---|---|---|---|---|
| JNJ | Johnson & Johnson | 154.64 | +0.36 | +0.23% | 16:00 GMT-4 | 6.09M | 7.46M | 372.17B |
| ABBV | AbbVie Inc. | 166.42 | +2.07 | +1.26% | 16:00 GMT-4 | 4.95M | 5.61M | 293.88B |
| PFE | Pfizer Inc. | 28.64 | -0.28 | -0.97% | 16:01 GMT-4 | 25.66M | 42.47M | 162.29B |
| SNY | Sanofi | 48.67 | -0.15 | -0.31% | 16:00 GMT-4 | 613.41k | 1.99M | 122.80B |
| REGN | Regeneron Pharmaceuticals, Inc. | 982.29 | +14.31 | +1.48% | 16:00 GMT-4 | 386.46k | 455.40k | 108.23B |
| GSK | GlaxoSmithKline plc | 44.98 | +0.10 | +0.22% | 16:00 GMT-4 | 1.87M | 3.15M | 93.80B |
| GILD | Gilead Sciences, Inc. | 67.72 | -0.14 | -0.21% | 16:00 GMT-4 | 3.57M | 6.97M | 84.37B |
| MRNA | Moderna, Inc. | 132.9 | +0.22 | +0.17% | 16:00 GMT-4 | 2.70M | 3.82M | 50.93B |
| TAK | Takeda Pharmaceutical Company Limited | 13.22 | -0.09 | -0.68% | 16:00 GMT-4 | 1.01M | 1.65M | 41.70B |
| BNTX | BioNTech SE | 90.61 | -2.37 | -2.55% | 16:00 GMT-4 | 471.65k | 591.09k | 21.84B |
| NVAX | Novavax, Inc. | 13.01 | -1.39 | -9.65% | 16:00 GMT-4 | 13.76M | 12.78M | 1.92B |
| VIR | Vir Biotechnology, Inc. | 9.73 | -0.20 | -2.01% | 16:00 GMT-4 | 624.61k | 988.40k | 1.32B |
| INO | Inovio Pharmaceuticals, Inc. | 12 | -0.79 | -6.18% | 16:00 GMT-4 | 414.23k | 443.72k | 310.93M |
Business WireInvestigational Seladelpar Demonstrates Significant Improvements in Liver Disease Progression and Reduced Itching in Primary Biliary Cholangitis
FOSTER CITY, Calif., May 18, 2024--Gilead Sciences, Inc. (Nasdaq: GILD), following the recent acquisition of CymaBay Therapeutics, Inc., today announced interim results from the ongoing ASSURE study demonstrating treatment with seladelpar, an investigational PPAR delta agonist, led to improvements in markers of cholestasis and reduced inflammation. Additional findings demonstrate that seladelpar can help reduce pruritus (itch) in people living with primary biliary cholangitis (PBC). There are cu
- Thomson Reuters StreetEvents
Q1 2024 Autolus Therapeutics PLC Earnings Call
Q1 2024 Autolus Therapeutics PLC Earnings Call
Sign in to view your followed lists
© 2024 Yahoo. All rights reserved.